C tier · mixed
Unusually large randomised trial base for a compound of this type, but the flagship indication failed: Cochrane found no benefit on death or disability in acute ischaemic stroke, flagged an increase in non-fatal serious adverse events, and documented manufacturer involvement in the pivotal trials.
cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids produced by enzymatic breakdown of porcine brain tissue, marketed in parts of Europe and Asia for stroke, dementia and traumatic brain injury. The randomised evidence is substantial in volume but, in the indication studied most rigorously, Cochrane reviewers concluded it probably confers no benefit.
the explanation
It is a liquid made from pig brain protein that has been broken down into small fragments, given by injection in some countries for stroke and memory problems. Independent reviewers who pooled the trials found it did not appear to reduce death or disability after stroke, and most of those trials had ties to the company that makes it.
regulatory status
Not FDA- or EMA-approved; marketed in some other jurisdictions
Cerebrolysin is not approved by the US FDA and is not centrally authorised by the EMA. It is manufactured by Ever Pharma (Unterach, Austria) and is prescribed in Russia, parts of Eastern Europe, China and other Asian markets, where its precise national approval status varies and is not uniformly documented.
how it works · proposed mechanism
Cerebrolysin is proposed to act as a neurotrophic-factor mimetic, but it is a heterogeneous mixture with no identified single active component.
Neurotrophic factor mimicry
The preparation is described as containing peptide fragments with activity resembling BDNF, GDNF, NGF and CNTF. This attribution comes largely from in vitro and animal assays rather than from isolation and characterisation of the responsible molecules.
Anti-apoptotic and anti-excitotoxic claims
Preclinical work reports reduced neuronal apoptosis, attenuated calpain activation and limited excitotoxic injury in ischaemia models. Translation of these findings to human stroke outcomes has not been demonstrated in the pooled randomised evidence.
Undefined active moiety
Because Cerebrolysin is an enzymatic hydrolysate rather than a single defined chemical entity, batch composition and the identity of any active peptide remain uncharacterised in the public literature. This makes mechanistic claims difficult to test and difficult to falsify.
what’s reported
evidence shape
5 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The trial literature is large enough to look reassuring by volume, but the most methodologically careful synthesis of it concluded there is probably no benefit in acute ischaemic stroke, alongside a signal of increased non-fatal serious adverse events. The manufacturer supported three of the pivotal multicentre trials by supplying drug and placebo, randomisation codes, research grants or statisticians, which is exactly the pattern that inflates apparent effect sizes.
key published findings
- Human trial evidence (Cochrane 2023 systematic review, 7 RCTs, 1,773 participants): Cerebrolysin or Cerebrolysin-like peptide mixtures showed no reduction in all-cause death in acute ischaemic stroke, RR 0.96 (95% CI 0.65 to 1.41), moderate-certainty evidence; the reviewers concluded the drug probably has no beneficial effect on preventing all-cause death.
- Human trial evidence (same review): total serious adverse events RR 1.16 (95% CI 0.81 to 1.66), fatal serious adverse events RR 0.90 (95% CI 0.59 to 1.38), but non-fatal serious adverse events were increased at RR 2.39 (95% CI 1.10 to 5.23).
- Human trial evidence (Cochrane 2019 review, vascular dementia, 6 RCTs, 597 participants): pooled results suggested a beneficial effect on cognition and on global clinical impression, but every outcome was graded very low quality under GRADE and all studies with disclosed funding were pharmaceutical-industry supported.
- Methodological finding (Cochrane 2023): most included stroke studies carried unclear or high risk of bias across multiple domains, with attrition of 16 to 29 percent in several trials, and the manufacturer supported three of the multicentre studies through drug and placebo supply, randomisation codes, research grants or statisticians.
- Composition finding: the product is an enzymatic hydrolysate of purified porcine brain protein rather than a defined chemical entity, so no CAS number, molecular formula or molar mass applies to the preparation as a whole.
limitations of the evidence
- No single active molecule has been isolated, so batch-to-batch consistency and mechanistic claims cannot be independently verified from the public literature.
- The positive signals sit in indications (vascular dementia, traumatic brain injury) where the evidence is graded very low certainty, while the indication with moderate-certainty evidence is negative.
- Industry sponsorship of the pivotal multicentre trials, combined with high attrition, means residual bias in favour of the drug cannot be excluded.
documented safety signals
- Cochrane 2023 reported an increase in non-fatal serious adverse events, RR 2.39 (95% CI 1.10 to 5.23), described as spontaneous adverse effects requiring hospitalisation.
- As a biologically derived porcine protein hydrolysate given parenterally, hypersensitivity and injection-site reactions are inherent product risks.
- The absence of FDA or EMA review means no independent regulatory safety dossier is publicly available in those jurisdictions.
identity
| full name | Cerebrolysin (porcine brain-derived peptide preparation, FPF-1070) |
| category | Cognitive |
| modality | peptide |
laboratory handling
| storage | Supplied as a sterile aqueous ampoule solution; commercial labelling specifies protection from light and storage below 25 C, with no freezing. This is product-handling information only. |
| solubility | Supplied pre-dissolved as an aqueous solution; the preparation is a water-soluble mixture of free amino acids and low-molecular-weight peptides. |
| co-studied with | No randomised trial has evaluated Cerebrolysin in deliberate combination with other investigational peptides; combination data of any kind are absent from the reviewed literature. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedCochrane Database of Systematic Reviews · 2023 · systematic review
Cochrane Database of Systematic Reviews (PMC10565895) · 2023 · systematic review
Cochrane · 2023 · systematic review summary
Cochrane Database of Systematic Reviews · 2019 · systematic review
Cochrane · 2019 · systematic review summary
others in Cognitive